Design Issues in Randomized Clinical Trials of Maintenance Therapies.

about

Design Issues in Randomized Clinical Trials of Maintenance Therapies.

Item

http://www.wikidata.org/entity/Q36848078

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Design Issues in Randomized Clinical Trials of Maintenance Therapies.

@en

type

Item

label

Design Issues in Randomized Clinical Trials of Maintenance Therapies.

@en

prefLabel

Design Issues in Randomized Clinical Trials of Maintenance Therapies.

@en

P1476

Design Issues in Randomized Clinical Trials of Maintenance Therapies.

@en

P2093

Edward L Korn

http://www.w3.org/2001/XMLSchema#string

Richard F Little

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review

European perspective on multiple myeloma treatment strategies in 2014

Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.

Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.

A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patien

Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews.

Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

P31

scholarly article

P356

10.1093/JNCI/DJV225

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Boris Freidlin

P577

2015-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26286730

http://www.w3.org/2001/XMLSchema#string

P932

4849358

http://www.w3.org/2001/XMLSchema#string